If you invested in COVID-19 vaccine maker Moderna (NASDAQ: MRNA) last year, you're likely sitting on a fantastic return, as the stock is up more than 500% in 12 months (the S&P 500 has increased by just 31%). With a pricey valuation that's significantly higher than analyst price targets and a business that today is dependent on COVID-19, it may only be a matter of time before a correction takes place. Moderna could soon face more competition in the U.S.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting